Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
30.87%
Operating Margin
21.02%
Net Margin
14.42%
Efficiency Metrics
Revenue per Expense Ratio
1.27
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
30.81%
Income Tax Rate
-37.77%
EPS
5.3900000000
Balance Sheet Analysis
Current Ratio
2.53
Cash Ratio
1.88
Working Capital
$570.13M
Debt to Equity
6.16
Debt to Assets
67.57%
Equity Ratio
10.97%
Cash Flow Analysis
Operating Cash Flow Ratio
25.81%
Free Cash Flow Ratio
16.23%
CapEx to Revenue
9.58%
Dividends Paid
$176.00M
Stock Buybacks
$994.17M
Total Shareholder Returns
$1.17B
Cash Position Change
57.64%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 2,770.14%
Detailed Growth Metrics
Core Performance
Revenue
19.50%
Net Income
141.27%
EPS
130.34%
Operating Income
38.68%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
150.78%
Operating Cash Flow
32.65%
Free Cash Flow
6.01%
Balance Sheet Health
Assets
28.41%
Debt
17.33%
Book Value per Share
114.94%
Inventory
16.33%
Shareholder Returns
Dividends per Share
2,770.14%
Shares Outstanding
4.73%
Long Term Trends
3Y Revenue/Share
291.62%
5Y Revenue/Share
50.33%
3Y Dividend/Share
63.69%
5Y Dividend/Share
-9.33%